FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1052-1054 September 8, 2005 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bucaneve, G. PubMed Citation

Improved management of infectious complications of cancer has contributed substantially to the success of care over the past several decades. In the 1960s it became clear that neutropenia was highly correlated with the occurrence of rapidly progressive sepsis.¹ In the 1970s, strategies for empirical antibacterial therapy were devised to minimize these complications. This therapy was directed primarily against gram-negative rods, especially Pseudomonas aeruginosa, with good results.² Paradoxically, this strategy has caused gram-positive cocci to become the most frequent cause of bacteremia among patients with cancer. However, the need for empirical treatment of infections with gram-positive cocci is rare because they . . . [Full Text of this Article]

Related Letters:

Antibacterial Prophylaxis in Patients with Cancer and Neutropenia
Freifeld A. G., Sepkowitz K. A., Almyroudis N. G., Segal B. H., Castagna L., Santoro A., Pasqualotto A. C., Rosa D. D., Machado A. L., Ito J. I., Tegtmeier B. R., O'Donnell M. R., Eller P., Pechlaner C., Del Favero A., Bucaneve G., Martino P., Steven N., Billingham L., Cullen M., Baden L. R.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:90-94, Jan 5, 2006. Correspondence

This article has been cited by other articles:

• Kishel, J. J, Sivik, J. (2008). Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 14: 189-193 [Abstract]  
• Freifeld, A. G., Sepkowitz, K. A., Almyroudis, N. G., Segal, B. H., Castagna, L., Santoro, A., Pasqualotto, A. C., Rosa, D. D., Machado, A. L., Ito, J. I., Tegtmeier, B. R., O'Donnell, M. R., Eller, P., Pechlaner, C., Del Favero, A., Bucaneve, G., Martino, P., Steven, N., Billingham, L., Cullen, M., Baden, L. R. (2006). Antibacterial prophylaxis in patients with cancer and neutropenia.. NEJM 354: 90-94 [Full Text]  
• (2005). Prophylactic Levofloxacin for Neutropenic Cancer Patients?. JWatch Infect. Diseases 2005: 7-7 [Full Text]  
• (2005). Levofloxacin Averts Infections During Chemotherapy-Induced Neutropenia. JWatch General 2005: 3-3 [Full Text]